UMIN-CTR Clinical Trial

Basic information
Official scientific title of the study	Colonization or infection in MRSA positive sputum patients
Title of the study (Brief title)	treatment of MRSA positive sputum
Region	Japan

Condition
Condition	MRSA
Classification by specialty	Pneumology Infectious disease
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	In general wards, colinization or infections of MRSA were distingushed?
Basic objectives2	Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	treatments by MRSA drugs
Key secondary outcomes

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type	Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit	15 years-old <=
Age-upper limit	100 years-old >
Gender	Male and Female
Key inclusion criteria	MRSA sputume positive patients
Key exclusion criteria	None
Target sample size	100

Research contact person
Name of lead principal investigator	Masafumi SEKI
Organization	Tohoku pharmaceutical University Hospital
Division name	Respiratory and Infection
Address	Sendai
TEL	022-259-1221
Email	seki@hosp.tohoku-pharm.ac.jp

Public contact
Name of contact person	Masafumi SEKI
Organization	Tohoku pharmaceutical University Hospital
Division name	Respiratory and Infection
Address	Sendai
TEL	022-259-1221
Homepage URL
Email	seki@hosp.tohoku-pharm.ac.jp

Sponsor
Institute	Tohoku pharmaceutical University
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization	Scientific budgets
Organization
Division
Category of Funding Organization	Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funｄer(s)

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2015 Year 07 Month 15 Day

Progress
Recruitment status	Open public recruiting
Date of protocol fixation	2015 Year 07 Month 08 Day
Anticipated trial start date	2015 Year 07 Month 08 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results	Unpublished
URL releasing results
Results
Other related information	Sampling from inpatients

Management information
Registered date	2015 Year 07 Month 15 Day
Last modified on	2016 Year 07 Month 15 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021203